An interventional study of Best Practice and Communication Intervention in Bladder Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Health services research
This clinical trial tests the feasibility of an electronic health record (EHR) integrated remote patient monitoring intervention to reduce readmission for patients with bladder cancer undergoing cystectomy. Cystectomy is the preferred treatment for locally advanced bladder cancer and involves removal of the bladder, prostate or uterus and part of vagina, and pelvic lymph nodes along with reconstruction of the urinary tract using a segment of bowel. Hospital readmission rates following cystectomy exceed 25% and are among the highest of any surgery. A significant barrier to identifying complications early arises from our inability to monitor patients once they are discharged from the hospital. The EHR integrated remove patient monitoring intervention helps with monitoring of symptoms after a patient's discharge from a cystectomy procedure and provides a direct line of communication between patients and their care team when concerning symptoms arise. This may reduce readmission rate for patients with bladder cancer undergoing cystectomy.
1,798 studies on the registry are indexed under Urinary Bladder Neoplasms; 445 are open to participants now.
This study's planned enrollment of 50 is below the median of 60 across 1,296 interventional studies indexed under Urinary Bladder Neoplasms.
Browse Urinary Bladder Neoplasms studies →University of Michigan Rogel Cancer Center is the lead sponsor of 323 studies on the registry; 47 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 31 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Patients receive access to the MyUofMHealth App and, starting at discharge, receive notifications, up to 3 times per day with frequency decreasing to daily, then less frequently over time, prompting them to complete medication and pain assessments, record food and fluid intake and exercise and triage/symptom tracking, and provide a direct line of communication to their care team if concerning symptoms arise, up to day 35 post discharge.
Other: Communication Intervention · Other: Interview · Behavioral: Smartphone Application-based Intervention · Other: Supportive Care · Other: Survey Administration
Patients receive access to the MyUofMHealth App and undergo standard post-operative care.
Other: Best Practice · Other: Interview · Behavioral: Smartphone Application-based Intervention · Other: Survey Administration
Undergo standard post-operative care
Also known as: standard of care, standard therapy
Communicate with care team
Ancillary studies
Receive access to the MyUofMHealth App
Also known as: Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention
Receive notifications
Also known as: Smartphone App-based Intervention, Smartphone Intervention, Smartphone-based Intervention
Complete assessments
Also known as: Supportive Therapy, Symptom Management, Therapy, Supportive
Ancillary studies
Trial randomization meeting goal of 50 patients (feasibility)
Will be reported as number of participants accrued and randomized.
Time frame: Up to 6 months
Intervention deployment in > 90% of patients randomized to intervention arm (feasibility)
Will be reported as proportions with the associated 95% binomial confidence intervals.
Time frame: Up to 6 months
Trial enrollment of ≥ 50% of eligible patients (acceptability)
Will be reported as proportions with the associated 95% binomial confidence intervals.
Time frame: Up to 6 months
Hospital free days
A hospital day will be a day that includes an emergency department visit or acute care hospital or hospitalization within 90 days from discharge. A hospital-free day will be any day that is not a hospital day and when a patient is alive. Will be reported by arm using a median or mean, and effect sizes will be calculated and their associated confidence intervals.
Time frame: Up to 90 days from discharge
Plan to share: Yes — we will share a de-identified version of the quantitative data, including the data output from the application (e.g., frequency of patient engagement, patient symptoms, pain medications, etc.) and the responses to both the PROMIS and satisfaction questionnaires.
Supporting information: Study protocol, Clinical study report, Analytic code
Time frame: for up to 10 years
Access criteria: For interested researchers
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.
Of 235 non-industry interventional studies with no phase under Urinary Bladder Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 70. This study's planned 18 months is below that.
Counting every sponsor, half of 244 studies reached it within 39 months; a quarter within 20 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center →